A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
| Condition | Diabetes Mellitus, Type 2 |
|---|---|
| Phase | Phase 1 |
| Sponsor | Eli Lilly and Company |
| Status | Completed |
| Enrollment | 62 participants |
| Interventions | LY3502970 |
| Start date | Nov 12, 2021 |
| Completion date | Sep 5, 2022 |
| Results posted | Jul 16, 2026 |
Summary
The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
| Placebo - Part A | 2 Participants |
|---|---|
| 2 mg LY3502970 - Part A | 5 Participants |
| 3 mg LY3502970 - Part A | 5 Participants |
| Placebo QD - Part B | 4 Participants |
| 2(or 3)/3/6/12 mg LY3502970 QD - Part B | 11 Participants |
| 2/3/6/8/12/24 mg LY3502970 QD - Part B | 12 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
- Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Uric Acid Lowering Trial in Youth Onset T2D — University of Colorado, Denver
- Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1 — State University of New York at Buffalo
- Continuous Glucose Monitoring Following Hospital Discharge — Kathleen Dungan
- Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on I — University of Colorado, Denver